Reset
Showing 6 of 6 academic articles

CRISPR/Cas9 for hepatitis B virus infection treatment

Bo Cai, Shixue Chang, Yuhan Tian, Shuai Zhen • Immunity, Inflammation and Disease (2023)

Abstract Hepatitis B virus (HBV) infection remains a global health challenge. Despite the availability of effective preventive vaccines, millions of people are at risk of cirrhosis and hepatocellular carcinoma. Current drug therapies inhibi...

DOAJ Open Access (DOAJ) DOI: 10.1002/iid3.866

Study on seroprevalence of hepatitis delta in a regional hospital in western Turkey

Sukran Kose, Gulfem Ece, Ayhan Gozaydin, Melda Turken • Journal of Infection in Developing Countries (2012)

Introduction: Hepatitis delta virus (HDV) is an incomplete virus dependent on hepatitis B virus (HBV) for its multiplication. It can infect individuals with active HBV infection and cause severe liver disease. It is less prevalent than hepa...

DOAJ Open Access (DOAJ) DOI: 10.3855/jidc.1749

MBOAT7-TMC4 rs641738 Is Not Associated With the Risk of Hepatocellular Carcinoma or Persistent Hepatitis B Infection

Peng Wang, Ying Li, Lu Li, Rong Zhong et al. • Frontiers in Oncology (2021)

ObjectiveA hot genetic variant, rs641738 within the membrane-bound O-acyltransferase domain containing 7(MBOAT7) and transmembrane channel-like 4 (TMC4), was recently reported to be associated with several liver diseases. However, the resul...

DOAJ Open Access (DOAJ) DOI: 10.3389/fonc.2021.639438

Case reports of latent HBV hepatitis in patients after neurosurgical treatment for hypothalamic and pituitary tumors

Kuniyasu Niizuma, Yoshikazu Ogawa, Takayuki Kogure, Teiji Tominaga • BMC Infectious Diseases (2020)

Abstract Background Hepatitis B virus (HBV) infection is a major public health problem worldwide. More than 2 billion people have been exposed to HBV, and about 257 million individuals are chronic carriers of HBV. HBV reactivation has been ...

DOAJ Open Access (DOAJ) DOI: 10.1186/s12879-020-04971-2